Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients

Vascular Pharmacology

Volumn 67, Issue , 2015, Pages 21-29

  Fadini, Gian Paolo ^a,b   Rigato, Mauro ^a   Boscari, Federico ^a   Cappellari, Roberta ^a   Menegazzo, Lisa ^a,b   Pilutti, Chiara ^a   Iori, Elisabetta ^a   Marescotti, Mariacristina ^a   Plebani, Mario ^a   Albiero, Mattia ^b   Avogaro, Angelo ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Angiogenesis; Lipids; Regeneration; Stem cells; Therapy

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHOLESTEROL; FLUINDOSTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PROTEIN KINASE B; ROSUVASTATIN; SIMVASTATIN; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; TRIACYLGLYCEROL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOGENESIS; ANGIOGENESIS ASSAY; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL COUNT; CELL POLARITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVATION; FEMALE; GRANULOCYTE; HUMAN; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANIMAL; BLOOD; CELL CULTURE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; MOUSE; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELLS, CULTURED; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; TIME FACTORS;

EID: 84929292480     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.11.005     Document Type: Article

References (46)

1. Seshasai S.R., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., Sarwar N., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841.
2. Avogaro A., Albiero M., Menegazzo L., de Kreutzenberg S., Fadini G.P. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 2011, 34(Suppl. 2):S285-S290.
3. Fadini G.P., Losordo D., Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 2012, 110:624-637.
4. Fadini G.P., Boscaro E., de Kreutzenberg S., Agostini C., Seeger F., Dimmeler S., et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010, 33:1097-1102.
5. Fadini G.P., Sartore S., Albiero M., Baesso I., Murphy E., Menegolo M., et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006, 26:2140-2146.
6. Fadini G.P., Maruyama S., Ozaki T., Taguchi A., Meigs J., Dimmeler S., et al. Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One 2010, 5:e11488.
7. Fadini G.P., Avogaro A. Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes Obes Metab 2010, 12:570-583.
8. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001, 103:2885-2890.
9. Landmesser U., Engberding N., Bahlmann F.H., Schaefer A., Wiencke A., Heineke A., et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004, 110:1933-1939.
10. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirchhoff N., Schulz S., et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363.
11. Fichtlscherer S., Schmidt-Lucke C., Bojunga S., Rossig L., Heeschen C., Dimmeler S., et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006, 27:1182-1190.
12. Steinmetz M., Pelster B., Lucanus E., Arnal J.F., Nickenig G., Werner N. Atorvastatin-induced increase in progenitor cell levels is rather caused by enhanced receptor activator of NF-kappaB ligand (RANKL) cell proliferation than by bone marrow mobilization. J Mol Cell Cardiol 2013, 57:32-42.
13. Westerterp M., Gourion-Arsiquaud S., Murphy A.J., Shih A., Cremers S., Levine R.L., et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 2012, 11:195-206.
14. Hristov M., Fach C., Becker C., Heussen N., Liehn E.A., Blindt R., et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis 2007, 192:413-420.
15. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
16. Fadini G.P., Albiero M., Vigili de Kreutzenberg S., Boscaro E., Cappellari R., Marescotti M., et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 2013, 36:943-949.
17. Case J., Mead L.E., Bessler W.K., Prater D., White H.A., Saadatzadeh M.R., et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007, 35:1109-1118.
18. Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D.N., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80.
19. Fadini G.P., Cappellari R., Mazzucato M., Agostini C., Vigili de Kreutzenberg S., Avogaro A. Monocyte-macrophage polarization balance in pre-diabetic individuals. Acta Diabetol 2013, 50:977-982.
20. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
21. Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005, 353:999-1007.
22. Mund J.A., Estes M.L., Yoder M.C., Ingram D.A., Case J. Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells. Arterioscler Thromb Vasc Biol 2012, 32:1045-1053.
23. Jetten N., Verbruggen S., Gijbels M.J., Post M.J., De Winther M.P., Donners M.M. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis 2014, 17:109-118.
24. Hur J., Yang H.M., Yoon C.H., Lee C.S., Park K.W., Kim J.H., et al. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. Circulation 2007, 116:1671-1682.
25. Menegazzo L., Albiero M., Millioni R., Tolin S., Arrigoni G., Poncina N., et al. Circulating myeloid calcifying cells have antiangiogenic activity via thrombospondin-1 overexpression. FASEB J 2013, 27:4355-4365.
26. Raymond C., Cho L., Rocco M., Hazen S.L. New cholesterol guidelines: worth the wait?. Cleve Clin J Med 2014, 81:11-19.
27. Zhang H., Plutzky J., Skentzos S., Morrison F., Mar P., Shubina M., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013, 158:526-534.
28. Lamberts E.J., Nijpels G., Welschen L.M., Hugtenburg J.G., Dekker J.M., Souverein P.C., et al. Discontinuation of statins among patients with type 2 diabetes. Diabetes Metab Res Rev 2012, 28:241-245.
29. Gomez Sandoval Y.H., Braganza M.V., Daskalopoulou S.S. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des 2011, 17:3669-3689.
30. Pineda A., Cubeddu L.X. Statin rebound or withdrawal syndrome: does it exist?. Curr Atheroscler Rep 2011, 13:23-30.
31. McGowan M.P. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004, 110:2333-2335.
32. Jasinska-Stroschein M., Owczarek J., Wejman I., Orszulak-Michalak D. Novel mechanistic and clinical implications concerning the safety of statin discontinuation. Pharmacol Rep 2011, 63:867-879.
33. Li J.J., Li Y.S., Chen J., Yang J.Q. Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Med Hypotheses 2006, 66:1199-1204.
34. Lee K.T., Lai W.T., Chu C.S., Tsai L.Y., Yen H.W., Voon W.C., et al. Effect of withdrawal of statin on C-reactive protein. Cardiology 2004, 102:166-170.
35. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001, 108:391-397.
36. Westerterp M., Bochem A.E., Yvan-Charvet L., Murphy A.J., Wang N., Tall A.R. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ Res 2014, 114:157-170.
37. Gomes A.L., Carvalho T., Serpa J., Torre C., Dias S. Hypercholesterolemia promotes bone marrow cell mobilization by perturbing the SDF-1:CXCR4 axis. Blood 2010, 115:3886-3894.
38. Yvan-Charvet L., Pagler T., Gautier E.L., Avagyan S., Siry R.L., Han S., et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010, 328:1689-1693.
39. Tolani S., Pagler T.A., Murphy A.J., Bochem A.E., Abramowicz S., Welch C., et al. Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children. Atherosclerosis 2013, 229:79-85.
40. Su K.H., Shyue S.K., Kou Y.R., Ching L.C., Chiang A.N., Yu Y.B., et al. beta Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol 2011, 226:3330-3339.
41. Bennis Y., Sarlon-Bartoli G., Guillet B., Lucas L., Pellegrini L., Velly L., et al. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J Thromb Haemost 2012, 10:1914-1928.
42. Aicher A., Rentsch M., Sasaki K., Ellwart J.W., Fandrich F., Siebert R., et al. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res 2007, 100:581-589.
43. Fadini G.P., Miotto D., Baesso I., Facco M., Miorin M., Tiengo A., et al. Arterio-venous gradient of endothelial progenitor cells across renal artery stenosis. Atherosclerosis 2005, 182:189-191.
44. Madonna R., De Caterina R. In vitro neovasculogenic potential of resident adipose tissue precursors. Am J Physiol Cell Physiol 2008, 295:C1271-C1280.
45. Ingram D.A., Mead L.E., Moore D.B., Woodard W., Fenoglio A., Yoder M.C. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 2005, 105:2783-2786.
46. Scadden D.T. Nice neighborhood: emerging concepts of the stem cell niche. Cell 2014, 157:41-50.